<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763503</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.18118</org_study_id>
    <nct_id>NCT00763503</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis</brief_title>
  <official_title>Pharmacokinetic and Pharmacodynamic Study of CD 2027 3µg/g Oily Spray Applied Twice Daily for 3 Weeks Under Conditions of Maximized Use in Adults With Plaque-type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label study to assess systemic plasma levels of calcitriol,
      calcium homeostasis and safety in adults with plaque-type psoriasis under conditions of
      maximized use of CD 2027 3µg/g oily spray twice daily (6 g daily), applied to 20% of BSA for
      3 weeks.

      There are a total of six visits: Pre-treatment period (Day -15, Day -8 and Day -1) and
      Treatment period (Day 1/ Baseline, Day 15 and Day 22).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD 2027 plasma concentrations</measure>
    <time_frame>0, 1, 2, 3, 4, 6, 9, 12 hour time points</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calcium homeostasis</measure>
    <time_frame>Screening, Day -8, -1 and prior to the morning application on Day 1, 15 and 22</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Plaque-type Psoriasis</condition>
  <arm_group>
    <arm_group_label>CD 2027</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD 2027</intervention_name>
    <description>3µg/g Oily Spray</description>
    <arm_group_label>CD 2027</arm_group_label>
    <other_name>Calcitriol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of plaque-type psoriasis involving 10% - 20% of body surface area (BSA),
             with a Global Severity Score of at least 3 (moderate)

        Exclusion Criteria:

          -  Other type of psoriasis (other than plaque)

          -  Significant abnormal lab findings

          -  Secondary hyperparathyroidism

          -  Vit D deficiency

          -  Hypercalcemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arizona</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J &amp; S Studies</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <disposition_first_submitted>October 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>October 13, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 19, 2010</disposition_first_posted>
  <last_update_submitted>January 6, 2012</last_update_submitted>
  <last_update_submitted_qc>January 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>PK</keyword>
  <keyword>calcitriol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

